Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego. The presentation, to be held at a yet-to-be-specified date, focuses on tissue concentration–driven effects and organ-specific outcomes beyond traditional plasma pharmacokinetics. This research underscores the importance of understanding tissue-level drug distribution in determining toxicity profiles and supports the development of improved delivery strategies, including intravenous and nanoparticle-based formulations.
The findings are expected to have significant implications for the field of nanomedicine, as they highlight how drug accumulation in specific tissues can influence therapeutic outcomes and adverse effects. By moving beyond standard plasma concentration measurements, Sapu Nano aims to provide a more comprehensive understanding of drug behavior in the body. This could lead to the design of safer and more effective nanoparticle carriers that target drugs to diseased tissues while minimizing off-target toxicity.
Everolimus is a widely used mTOR inhibitor for various cancers and immunosuppression, but its clinical use is limited by side effects such as stomatitis, metabolic disturbances, and interstitial lung disease. The new data may help explain why certain toxicities occur and how they can be mitigated through optimized delivery systems. For Oncotelic, this research aligns with its broader strategy of leveraging AI-driven drug development and rare pediatric cancer treatments, including its work on diffuse intrinsic pontine glioma (DIPG) and melanoma.
Oncotelic, formerly known as Mateon Therapeutics, has a portfolio that includes OT-101 for DIPG, CA4P for melanoma, and OXi 4503 for acute myeloid leukemia. The company also acquired PointR Data Inc. in 2019 to build an AI-driven biotechnology platform, and AL-101 for intranasal apomorphine delivery targeting Parkinson's disease and other conditions. The everolimus toxicology study is part of Sapu Nano's mission to develop next-generation nanomedicine platforms that improve drug delivery and therapeutic index.
The presentation at SOT 2026 is a critical step in validating Sapu Nano's approach. By demonstrating that tissue concentration, not just plasma levels, drives toxicity, the company hopes to accelerate the development of safer nanomedicines. This could have broad applications beyond everolimus, potentially improving the safety and efficacy of many drugs that suffer from poor distribution or high toxicity. For investors, the data reinforces Oncotelic's commitment to innovation in oncology and nanomedicine.
For more information, visit the company's newsroom at https://ibn.fm/OTLC. The full press release can be accessed at https://ibn.fm/kZzE3.
